IL10 and lung carcinoma: The MDSCs inhibited the effector T cells, promoted angiogenesis, and were associated with an increased expression of immunomodulators such as programmed cell death 1 ligand 1 (PD-L1), arginase 1 (ARG1), cytotoxic T-lymphocyte antigen 4 (CTLA4), interleukin 10 (IL-10), IL-6, and lymphocyte-activation gene 3 (LAG3) in a murine model of lung cancer [76].